Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 125Gynecologic 7Genitourinary 6Thoracic 4Gastrointestinal 4Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Dermatologic 2Sarcoma 1Plasma cell 1Classical hematology 1

Conditions

Lymphoma, Non-Hodgkin 17Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Lymphoma, Large-Cell, Immunoblastic 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Breast Neoplasms 4Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Sezary Syndrome 2Sarcoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

pembrolizumab 4Paclitaxel 2vocimagene amiretrorepvec 1stenoparib 1olaparib 1mirabegron 1epacadostat 1durvalumab 1ciforadenant 1cemiplimab 1atezolizumab 1advexin 1Temozolomide 1Rituximab 1Pharmacogenomic Variants 1Nivolumab 1LTX-315 1Ipilimumab 1IACS-010759 1HMPL-013 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Carboplatin 1Capecitabine 1CPI-006 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1Antibodies 1AZD5153 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Paclitaxel × Lymphoid × Clear all
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1/2 Completed
41 enrolled
BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡